Block GA, et al.. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208–2218.

• PubMed
Block GA, . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208–2218.)| false
• Search Google Scholar
• Export Citation

Gutierrez OM, et al.. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584–592.

• PubMed
Gutierrez OM, . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584–592.)| false
• Search Google Scholar
• Export Citation

Navaneethan SD, et al.. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54:619–637.

• PubMed
Navaneethan SD, . Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54:619–637.)| false
• Search Google Scholar
• Export Citation

Koiwa F, et al.. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9:336–339.

• PubMed
Koiwa F, . Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9:336–339.)| false
• Search Google Scholar
• Export Citation

Sprague SM, et al.. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63:1483–1490.

• PubMed
Sprague SM, . Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63:1483–1490.)| false
• Search Google Scholar
• Export Citation

Block GA, et al.. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516–1525.

• PubMed
Block GA, . Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516–1525.)| false
• Search Google Scholar
• Export Citation

Palmer SC, et al.. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013; 10:e1001436.

• PubMed
Palmer SC, . Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013; 10:e1001436.)| false
• Search Google Scholar
• Export Citation

Block GA, et al.. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. J Am Med Assoc 2017; 317:156–164.

• PubMed
Block GA, . Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. J Am Med Assoc 2017; 317:156–164.)| false
• Search Google Scholar
• Export Citation

Isakova T, et al.. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2017; 70:737–751.

• PubMed
Isakova T, . KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2017; 70:737–751.)| false
• Search Google Scholar
• Export Citation

Cunningham J, et al.. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:1793–1800.

• PubMed
Cunningham J, . Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:1793–1800.)| false
• Search Google Scholar
• Export Citation

Chertow GM, et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482–2494.

• PubMed
Chertow GM, . Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482–2494.)| false
• Search Google Scholar
• Export Citation

Parfrey PS, et al.. The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 2015; 10:791–799.

• PubMed
Parfrey PS, . The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 2015; 10:791–799.)| false
• Search Google Scholar
• Export Citation

Friedl C, et al.. Mortality in dialysis patients with cinacalcet use: large observational registry study. Eur J Intern Med 2017; 42:89–95.

• PubMed
Friedl C, . Mortality in dialysis patients with cinacalcet use: large observational registry study. Eur J Intern Med 2017; 42:89–95.)| false
• Search Google Scholar
• Export Citation

Alem AM, et al.. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:396–399.

• PubMed
Alem AM, . Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:396–399.)| false
• Search Google Scholar
• Export Citation

Behets GJ, et al.. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 87:846–856.

• PubMed
Behets GJ, . Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 87:846–856.)| false
• Search Google Scholar
• Export Citation

Moe SM, et al.. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE Trial. J Am Soc Nephrol 2015; 26:1466–1475.

• PubMed
Moe SM, . Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE Trial. J Am Soc Nephrol 2015; 26:1466–1475.)| false
• Search Google Scholar
• Export Citation